| Name | Title | Contact Details |
|---|
Civetta Therapeutics was founded by William Sellers (Broad Institute and Dana-Farber Cancer Institute) and Eric Fischer (Dana Farber Cancer Institute and Harvard Medical School) to advance new medicines through small molecule intervention targeting propeller domains with the goal of developing important therapeutics for cancer and other indications.
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.
HiFiBiO SAS commercializes proprietary single cell technologies for applications in drug and biomarker discovery and development.
Psychemedics (NASDAQ: PMD) is the world`s leading drug testing company using hair for the detection of drugs of abuse. Psychemedics has been successfully operating for 30 years and thousands of corporations worldwide currently rely on Psychemedics` patented hair analysis technology for their pre-employment and employee drug screening. Psychemedics` clients include over 10% of the Fortune 500, some of the largest police departments in America, Federal Reserve Banks, and schools.
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.